Molecular Partners Toekomstige groei

Future criteriumcontroles 2/6

De winst van Molecular Partners zal naar verwachting dalen met 1.2% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 57.8% per jaar. De winst per aandeel zal naar verwachting groeien met 1.7% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -104.1% zijn.

Belangrijke informatie

-1.2%

Groei van de winst

1.7%

Groei van de winst per aandeel

Biotechs winstgroei	42.4%
Inkomstengroei	57.8%
Toekomstig rendement op eigen vermogen	-104.1%
Dekking van analisten	Low
Laatst bijgewerkt	01 Nov 2024

Recente toekomstige groei-updates

Recent updates

We're Keeping An Eye On Molecular Partners' (VTX:MOLN) Cash Burn Rate

Sep 10

We Think Some Shareholders May Hesitate To Increase Molecular Partners AG's (VTX:MOLN) CEO Compensation

Apr 11

Is Molecular Partners (VTX:MOLN) In A Good Position To Invest In Growth?

Jan 09

Here's Why We're Watching Molecular Partners' (VTX:MOLN) Cash Burn Situation

Sep 08

Need To Know: The Consensus Just Cut Its Molecular Partners AG (VTX:MOLN) Estimates For 2023

Jun 23

What You Need To Know About The Molecular Partners AG (VTX:MOLN) Analyst Downgrade Today

Aug 31

Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth Plans

May 09

Upgrade: Analysts Just Made A Substantial Increase To Their Molecular Partners AG (VTX:MOLN) Forecasts

Dec 26

We're Hopeful That Molecular Partners (VTX:MOLN) Will Use Its Cash Wisely

Jun 24

Molecular Partners AG (VTX:MOLN) Could Be Less Than A Year Away From Profitability

Mar 09

Analysts Just Made A Major Revision To Their Molecular Partners AG (VTX:MOLN) Revenue Forecasts

Feb 10

Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth Plans

Jan 21

How Much Of Molecular Partners AG (VTX:MOLN) Do Insiders Own?

Dec 17

Winst- en omzetgroeiprognoses

SWX:MOLN - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CHF Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	26	-72	-74	-40	2
12/31/2025	5	-69	-77	-61	3
12/31/2024	5	-59	-71	-64	3
9/30/2024	6	-63	-63	-62	N/A
6/30/2024	8	-58	-63	-62	N/A
3/31/2024	7	-59	-60	-60	N/A
12/31/2023	7	-62	-60	-59	N/A
9/30/2023	9	-60	-58	-57	N/A
6/30/2023	9	-62	-63	-62	N/A
3/31/2023	20	-50	-63	-62	N/A
12/31/2022	190	118	117	119	N/A
9/30/2022	189	117	112	114	N/A
6/30/2022	190	118	111	113	N/A
3/31/2022	182	106	101	102	N/A
12/31/2021	10	-64	-92	-91	N/A
9/30/2021	9	-67	-71	-69	N/A
6/30/2021	6	-72	-55	-54	N/A
3/31/2021	7	-66	-47	-46	N/A
12/31/2020	9	-63	-31	-29	N/A
9/30/2020	11	-53	-47	-45	N/A
6/30/2020	14	-48	-58	-56	N/A
3/31/2020	17	-43	-30	-28	N/A
12/31/2019	20	-36	-3	-1	N/A
9/30/2019	17	-37	0	1	N/A
6/30/2019	14	-38	2	4	N/A
3/31/2019	12	-38	-20	-19	N/A
12/31/2018	10	-37	-43	-42	N/A
9/30/2018	17	-27	-41	-41	N/A
6/30/2018	23	-18	N/A	-39	N/A
3/31/2018	22	-24	N/A	N/A	N/A
12/31/2017	20	-25	N/A	-40	N/A
9/30/2017	17	-26	N/A	N/A	N/A
6/30/2017	16	-28	N/A	-38	N/A
3/31/2017	19	-22	N/A	N/A	N/A
12/31/2016	23	-19	N/A	-35	N/A
9/30/2016	27	-13	N/A	N/A	N/A
6/30/2016	31	-3	N/A	18	N/A
3/31/2016	30	-2	N/A	N/A	N/A
12/31/2015	29	0	N/A	26	N/A
9/30/2015	28	-6	N/A	N/A	N/A
6/30/2015	25	-11	N/A	-24	N/A
3/31/2015	26	-5	N/A	N/A	N/A
12/31/2014	27	-2	N/A	-11	N/A
12/31/2013	32	7	N/A	-14	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat MOLN de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat MOLN de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat MOLN de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van MOLN ( 57.8% per jaar) zal naar verwachting sneller groeien dan de markt Swiss ( 4.2% per jaar).

Hoge groei-inkomsten: De omzet van MOLN ( 57.8% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat MOLN binnen 3 jaar verliesgevend zal zijn.

Molecular Partners Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus revenue estimates decrease by 62%, EPS upgraded

Price target decreased by 9.7% to CHF9.35

Price target increased by 11% to CHF10.35

Consensus revenue estimates fall by 45%

Consensus revenue estimates fall by 29%

Consensus revenue estimates decrease by 40%

Recent updates

Molecular Partners AG Presents Preclinical Proof-Of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024

Third quarter 2024 earnings released: CHF0.49 loss per share (vs CHF0.35 loss in 3Q 2023)

New minor risk - Shareholder dilution

Molecular Partners AG has completed a Follow-on Equity Offering in the amount of $20.000004 million.

Molecular Partners AG has filed a Follow-on Equity Offering in the amount of $20.000004 million.

We're Keeping An Eye On Molecular Partners' (VTX:MOLN) Cash Burn Rate

Consensus revenue estimates decrease by 62%, EPS upgraded

Second quarter 2024 earnings released: CHF0.46 loss per share (vs CHF0.49 loss in 2Q 2023)

Price target decreased by 9.7% to CHF9.35

Price target increased by 11% to CHF10.35

Molecular Partners Announces the Debut of their Lead Radio-Darpin Therapy (RDT) Candidate MP0712, Targeting DLL3

Molecular Partners AG Presents Positive Data from Completed Phase 1 Trial of MP0317 (FAP X CD40 DARPin) Monotherapy in Patients with Advanced Solid Tumors At ASCO 2024

First quarter 2024 earnings released: CHF0.34 loss per share (vs CHF0.45 loss in 1Q 2023)

Insufficient new directors

Molecular Partners AG Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of Action

Consensus revenue estimates fall by 45%

We Think Some Shareholders May Hesitate To Increase Molecular Partners AG's (VTX:MOLN) CEO Compensation

Full year 2023 earnings released: CHF1.89 loss per share (vs CHF3.63 profit in FY 2022)

Molecular Partners AG to Report First Half, 2024 Results on Aug 26, 2024

Consensus revenue estimates fall by 29%

Molecular Partners AG, Annual General Meeting, Apr 17, 2024

Is Molecular Partners (VTX:MOLN) In A Good Position To Invest In Growth?

Molecular Partners AG to Report Fiscal Year 2023 Final Results on Mar 14, 2024

Molecular Partners AG Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2A Trial of Mp0533 for Patients with Relapsed/Refractory AML and AML/MDS At ASH Annual Meeting

Molecular Partners AG Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting

New major risk - Share price stability

Molecular Partners Ag to Present Initial Data from Ongoing Phase 1/2A Trial of Mp0533 for Patients with Relapsed/Refractory Aml and Aml/Mds At the 65Th Ash Annual Meeting and Exposition

Third quarter 2023 earnings released: CHF0.35 loss per share (vs CHF0.41 loss in 3Q 2022)

Consensus revenue estimates decrease by 40%

Here's Why We're Watching Molecular Partners' (VTX:MOLN) Cash Burn Situation

Second quarter 2023 earnings released: CHF0.49 loss per share (vs CHF0.14 loss in 2Q 2022)

Molecular Partners AG Announces Executive Changes

Need To Know: The Consensus Just Cut Its Molecular Partners AG (VTX:MOLN) Estimates For 2023

Consensus revenue estimates fall by 12%

First quarter 2023 earnings released: CHF0.45 loss per share (vs CHF4.74 profit in 1Q 2022)

Consensus revenue estimates decrease by 73%, EPS upgraded

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Molecular Partners Initiates Clinical Study of Trispecific Candidate Mp0533 for the Treatment of Acute Myeloid Leukemia

Molecular Partners AG Presents New Preclinical Data Supporting its MP0533 DARPin T-Cell Engager for the Treatment of AML

Price target decreased to CHF12.87

High number of new directors

Molecular Partners AG Presents Positive Interim Safety and Mechanistic Data from Ongoing Phase 1 Trial of MP0317 for Treatment of Solid Tumors

Third quarter 2022 earnings released: CHF0.41 loss per share (vs CHF0.38 loss in 3Q 2021)

Molecular Partners AG Announces Continued Progress Across Oncology Programs with First Clinical Data Expected from Phase 1 Trial of MP0317 and Initiation of Phase 1 Trial of MP0533 Anticipated by Year-End

Investor sentiment improved over the past week

Consensus forecasts updated

What You Need To Know About The Molecular Partners AG (VTX:MOLN) Analyst Downgrade Today

Second quarter 2022 earnings released: CHF0.14 loss per share (vs CHF0.56 loss in 2Q 2021)

Price target increased to CHF30.57

Molecular Partners AG, Annual General Meeting, Apr 04, 2023

Johnson Fistel Files A Class Action Complain Against Molecular Partners AG

Molecular Partners AG Announces Publication in Nature Biotechnology Detailing Design and Mechanism of Ensovibep DARP in Antiviral for SARS-CoV-2

Price target increased to CHF30.57

Pomerantz Law Firm Announces the Filing of A Class Action Against Molecular Partners Ag and Certain Officers and Directors – Moln

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth Plans

Price target decreased to CHF26.83

High number of new directors

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Molecular Partners AG Announces Emergency Use Authorization Request for Ensovibep Submitted to the US Food and Drug Administration for the Treatment of Covid-19

Price target increased to CHF27.58

Novartis and Molecular Partners Report Positive Topline Data from Phase 2 Study for ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19

Forecast to breakeven in 2022

Price target decreased to CHF25.00

Upgrade: Analysts Just Made A Substantial Increase To Their Molecular Partners AG (VTX:MOLN) Forecasts

Molecular Partners Confirms Ensovibep Retains Neutralization of Omicron Variant of SARS-CoV-2 in Preclinical Studies

Molecular Partners Presents Results from a Phase 2a Trial of Ensovibep in 12 COVID-19 Patients

Third quarter 2021 earnings released: CHF0.38 loss per share (vs CHF0.67 loss in 3Q 2020)